4. Conclusions
chronic masticatory pain, myalgias, PNE, painless, pain
ADVERSE EFFECTS
The main objective of this 3-month prospective clinical trial was to evaluate the efficacy and safety of BTA in the treatment of refractory and localized MM compared to another minimally invasive treatment modality, such as PNE. In our study, these procedures were performed with the help of EMG prior to therapeutic administration. The results obtained showed a significant reduction in pain and an improvement in masticatory function. Our study revealed that it is possible to achieve satisfactory mouth opening and free and painless mandibular movement using both BTA and PNE in the treatment of chronic masticatory pain, with little or no adverse effects. The optimal use of BTA and PNE in patients with localized myalgias in the masticatory muscles could contribute to improving the efficiency of care in healthcare systems. Therefore, the use of BTA and PNE could be considered a valid and safe therapeutic alternative among the available options to treat refractory and localized MM when a better therapeutic response is expected, as both demonstrate high efficacy.